Immune Response "Der Durchbruch bei Aids" - 500 Beiträge pro Seite
eröffnet am 28.03.00 13:58:23 von
neuester Beitrag 28.03.00 22:25:25 von
neuester Beitrag 28.03.00 22:25:25 von
Beiträge: 5
ID: 105.454
ID: 105.454
Aufrufe heute: 0
Gesamt: 605
Gesamt: 605
Aktive User: 0
Top-Diskussionen
Titel | letzter Beitrag | Aufrufe |
---|---|---|
vor 1 Stunde | 2067 | |
vor 50 Minuten | 1996 | |
vor 1 Stunde | 1299 | |
vor 1 Stunde | 1209 | |
heute 06:46 | 1026 | |
vor 52 Minuten | 821 | |
20.04.24, 12:11 | 608 | |
vor 1 Stunde | 564 |
Meistdiskutierte Wertpapiere
Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
---|---|---|---|---|---|---|---|
1. | 1. | 18.048,56 | +0,66 | 243 | |||
2. | 2. | 1,1600 | -15,94 | 98 | |||
3. | 3. | 0,1890 | 0,00 | 97 | |||
4. | 5. | 9,2950 | +0,54 | 86 | |||
5. | 4. | 160,78 | +1,32 | 78 | |||
6. | 6. | 7,0000 | +0,03 | 42 | |||
7. | 11. | 6,7580 | +0,57 | 37 | |||
8. | 12. | 2.346,98 | +0,64 | 33 |
Nachzulesen unter Biotechwerte "IMNR Threads"
Hier etwas von Januar 2000.
Quelle: wallstreet-journal
Immune Response Signs Definitive Agreement to
Acquire Opticon Medical; Immune Shareholders
Approve Three Proposals At Special Shareholders
Meeting
ENGLEWOOD, Colo., Jan. 24 /PRNewswire/ -- Immune Response, Inc.
("Immune") (Nasdaq: IMUR) announced that it has signed a definitive
agreement to acquire privately held Opticon Medical, Inc. ("Opticon") through
a newly formed wholly owned subsidiary. Terms of the agreement call for the
existing stockholders of Immune to retain 20% of the newly merged company
on a post-merger basis through a tax-free exchange of stock. Upon
completion of the merger, the current officers and directors of Immune
Response will step down and a new board of directors chosen by Opticon will
take over. The current management of Opticon will operate the newly
merged company.
Opticon, based in Dublin, Ohio, is a development stage company focused on
the design, development and marketing of a series of innovative,
cost-effective devices for the management and control of adult urinary
incontinence and for use in traditional urinary management. Opticon
possesses the patents to an innovative product, the OPTICON(TM), a
disposable, silicone, indwelling valved catheter designed to prevent urine
leakage from the lower urinary tract. Unlike traditional urinary catheters, the
OPTICON does not require a system of urine collection bags and collecting
tubes.
"We are very excited to have the definitive agreement executed as we move
toward completing the transaction within the next few weeks," said William J.
Post, Opticon`s President. "This transaction will immediately enhance our
access to the public markets as we seek to make the all important step from
pure research and development to manufacturing and production."
Opticon is led by a team of officers and directors with extensive experience in
the healthcare industry. Mr. Post is a 23-year healthcare industry veteran
with significant experience in new business development and marketing. Mr.
Post has held executive level positions with healthcare companies such as
Medex, Inc., Ohmeda/BOC Healthcare and Spectramed, Inc.,
Instrumentation Laboratories, Inc. and Travenol-Genentech Diagnostics, a
division of Baxter. Opticon`s Chairman, Walter L. Sembrowich, Ph.D., is
President and founder of Aviex, Inc., a provider of investment and
development services to start-up and early stage medical companies. Dr.
Sembrowich is a founder of Diametrics Medical, Inc., a manufacturer and
marketer of a point-of-care blood analysis system, and is a director of St.
Jude Medical, a leader in cardiovascular products and technologies.
Closing of the transaction is subject to, among other things, successful
completion of final due diligence, completion of certain additional documents,
obtaining corporate and any necessary regulatory approvals, approval of the
transaction by Opticon`s shareholders, certain financing conditions, and other
customary pre-closing conditions.
Immune also announced today the results of its Special Meeting of
Shareholders held on January 20, 2000 in Denver, Colorado. At the meeting,
the Company`s shareholders approved three proposals including: a one for
three (1 for 3) reverse stock split of the Company`s common stock; a
reduction in the affirmative shareholder vote necessary to approve major
transactions from two-thirds to a majority of shares outstanding; and the
authorization to issue up to 1,000,000 shares of "blank check" preferred stock
and to increase the authorized capital of the Company to 26,000,000 shares.
The company is presently completing the paperwork necessary to effectuate
the reverse stock split and will announce the effective date in the near future.
The statements included in this press release concerning predictions of
economic performance and management`s plans and objectives constitute
forward-looking statements made pursuant to the safe harbor provisions of
Section 21E of the Securities Exchange Act of 1934, as amended, and Section
27A of the Securities Act of 1933, as amended. These statements involve
risks and uncertainties that could cause actual results to differ materially from
the forward-looking statements. Factors which could cause or contribute to
such differences include, but are not limited to, factors detailed in Immune`s
Securities and Exchange Commission filings; regulatory approvals; any
necessary stockholder approvals for either Immune or Opticon; economic
downturns affecting the operations of Immune or Opticon; the inability of
Opticon to receive necessary Regulatory approval for its products; the
inability to initiate or complete any contemplated restructuring, offering,
acquisition or other transaction; and the unavailability of financing to complete
management`s plans and objectives. The forward-looking statements
contained in this press release speak only as of the date hereof and the
Company disclaims any intent or obligation to update these forward-looking
statements.
/CONTACT: Joseph W. Hovorka, President of Immune Response, Inc.,
303-796-8139; or William J. Post, President of Opticon Medical, Inc.,
614-336-2000/
06:55 EST
MFG DJ-Cool
Quelle: wallstreet-journal
Immune Response Signs Definitive Agreement to
Acquire Opticon Medical; Immune Shareholders
Approve Three Proposals At Special Shareholders
Meeting
ENGLEWOOD, Colo., Jan. 24 /PRNewswire/ -- Immune Response, Inc.
("Immune") (Nasdaq: IMUR) announced that it has signed a definitive
agreement to acquire privately held Opticon Medical, Inc. ("Opticon") through
a newly formed wholly owned subsidiary. Terms of the agreement call for the
existing stockholders of Immune to retain 20% of the newly merged company
on a post-merger basis through a tax-free exchange of stock. Upon
completion of the merger, the current officers and directors of Immune
Response will step down and a new board of directors chosen by Opticon will
take over. The current management of Opticon will operate the newly
merged company.
Opticon, based in Dublin, Ohio, is a development stage company focused on
the design, development and marketing of a series of innovative,
cost-effective devices for the management and control of adult urinary
incontinence and for use in traditional urinary management. Opticon
possesses the patents to an innovative product, the OPTICON(TM), a
disposable, silicone, indwelling valved catheter designed to prevent urine
leakage from the lower urinary tract. Unlike traditional urinary catheters, the
OPTICON does not require a system of urine collection bags and collecting
tubes.
"We are very excited to have the definitive agreement executed as we move
toward completing the transaction within the next few weeks," said William J.
Post, Opticon`s President. "This transaction will immediately enhance our
access to the public markets as we seek to make the all important step from
pure research and development to manufacturing and production."
Opticon is led by a team of officers and directors with extensive experience in
the healthcare industry. Mr. Post is a 23-year healthcare industry veteran
with significant experience in new business development and marketing. Mr.
Post has held executive level positions with healthcare companies such as
Medex, Inc., Ohmeda/BOC Healthcare and Spectramed, Inc.,
Instrumentation Laboratories, Inc. and Travenol-Genentech Diagnostics, a
division of Baxter. Opticon`s Chairman, Walter L. Sembrowich, Ph.D., is
President and founder of Aviex, Inc., a provider of investment and
development services to start-up and early stage medical companies. Dr.
Sembrowich is a founder of Diametrics Medical, Inc., a manufacturer and
marketer of a point-of-care blood analysis system, and is a director of St.
Jude Medical, a leader in cardiovascular products and technologies.
Closing of the transaction is subject to, among other things, successful
completion of final due diligence, completion of certain additional documents,
obtaining corporate and any necessary regulatory approvals, approval of the
transaction by Opticon`s shareholders, certain financing conditions, and other
customary pre-closing conditions.
Immune also announced today the results of its Special Meeting of
Shareholders held on January 20, 2000 in Denver, Colorado. At the meeting,
the Company`s shareholders approved three proposals including: a one for
three (1 for 3) reverse stock split of the Company`s common stock; a
reduction in the affirmative shareholder vote necessary to approve major
transactions from two-thirds to a majority of shares outstanding; and the
authorization to issue up to 1,000,000 shares of "blank check" preferred stock
and to increase the authorized capital of the Company to 26,000,000 shares.
The company is presently completing the paperwork necessary to effectuate
the reverse stock split and will announce the effective date in the near future.
The statements included in this press release concerning predictions of
economic performance and management`s plans and objectives constitute
forward-looking statements made pursuant to the safe harbor provisions of
Section 21E of the Securities Exchange Act of 1934, as amended, and Section
27A of the Securities Act of 1933, as amended. These statements involve
risks and uncertainties that could cause actual results to differ materially from
the forward-looking statements. Factors which could cause or contribute to
such differences include, but are not limited to, factors detailed in Immune`s
Securities and Exchange Commission filings; regulatory approvals; any
necessary stockholder approvals for either Immune or Opticon; economic
downturns affecting the operations of Immune or Opticon; the inability of
Opticon to receive necessary Regulatory approval for its products; the
inability to initiate or complete any contemplated restructuring, offering,
acquisition or other transaction; and the unavailability of financing to complete
management`s plans and objectives. The forward-looking statements
contained in this press release speak only as of the date hereof and the
Company disclaims any intent or obligation to update these forward-looking
statements.
/CONTACT: Joseph W. Hovorka, President of Immune Response, Inc.,
303-796-8139; or William J. Post, President of Opticon Medical, Inc.,
614-336-2000/
06:55 EST
MFG DJ-Cool
Hier etwas von Januar 2000.
Quelle: wallstreet-journal
Immune Response Signs Definitive Agreement to
Acquire Opticon Medical; Immune Shareholders
Approve Three Proposals At Special Shareholders
Meeting
ENGLEWOOD, Colo., Jan. 24 /PRNewswire/ -- Immune Response, Inc.
("Immune") (Nasdaq: IMUR) announced that it has signed a definitive
agreement to acquire privately held Opticon Medical, Inc. ("Opticon") through
a newly formed wholly owned subsidiary. Terms of the agreement call for the
existing stockholders of Immune to retain 20% of the newly merged company
on a post-merger basis through a tax-free exchange of stock. Upon
completion of the merger, the current officers and directors of Immune
Response will step down and a new board of directors chosen by Opticon will
take over. The current management of Opticon will operate the newly
merged company.
Opticon, based in Dublin, Ohio, is a development stage company focused on
the design, development and marketing of a series of innovative,
cost-effective devices for the management and control of adult urinary
incontinence and for use in traditional urinary management. Opticon
possesses the patents to an innovative product, the OPTICON(TM), a
disposable, silicone, indwelling valved catheter designed to prevent urine
leakage from the lower urinary tract. Unlike traditional urinary catheters, the
OPTICON does not require a system of urine collection bags and collecting
tubes.
"We are very excited to have the definitive agreement executed as we move
toward completing the transaction within the next few weeks," said William J.
Post, Opticon`s President. "This transaction will immediately enhance our
access to the public markets as we seek to make the all important step from
pure research and development to manufacturing and production."
Opticon is led by a team of officers and directors with extensive experience in
the healthcare industry. Mr. Post is a 23-year healthcare industry veteran
with significant experience in new business development and marketing. Mr.
Post has held executive level positions with healthcare companies such as
Medex, Inc., Ohmeda/BOC Healthcare and Spectramed, Inc.,
Instrumentation Laboratories, Inc. and Travenol-Genentech Diagnostics, a
division of Baxter. Opticon`s Chairman, Walter L. Sembrowich, Ph.D., is
President and founder of Aviex, Inc., a provider of investment and
development services to start-up and early stage medical companies. Dr.
Sembrowich is a founder of Diametrics Medical, Inc., a manufacturer and
marketer of a point-of-care blood analysis system, and is a director of St.
Jude Medical, a leader in cardiovascular products and technologies.
Closing of the transaction is subject to, among other things, successful
completion of final due diligence, completion of certain additional documents,
obtaining corporate and any necessary regulatory approvals, approval of the
transaction by Opticon`s shareholders, certain financing conditions, and other
customary pre-closing conditions.
Immune also announced today the results of its Special Meeting of
Shareholders held on January 20, 2000 in Denver, Colorado. At the meeting,
the Company`s shareholders approved three proposals including: a one for
three (1 for 3) reverse stock split of the Company`s common stock; a
reduction in the affirmative shareholder vote necessary to approve major
transactions from two-thirds to a majority of shares outstanding; and the
authorization to issue up to 1,000,000 shares of "blank check" preferred stock
and to increase the authorized capital of the Company to 26,000,000 shares.
The company is presently completing the paperwork necessary to effectuate
the reverse stock split and will announce the effective date in the near future.
The statements included in this press release concerning predictions of
economic performance and management`s plans and objectives constitute
forward-looking statements made pursuant to the safe harbor provisions of
Section 21E of the Securities Exchange Act of 1934, as amended, and Section
27A of the Securities Act of 1933, as amended. These statements involve
risks and uncertainties that could cause actual results to differ materially from
the forward-looking statements. Factors which could cause or contribute to
such differences include, but are not limited to, factors detailed in Immune`s
Securities and Exchange Commission filings; regulatory approvals; any
necessary stockholder approvals for either Immune or Opticon; economic
downturns affecting the operations of Immune or Opticon; the inability of
Opticon to receive necessary Regulatory approval for its products; the
inability to initiate or complete any contemplated restructuring, offering,
acquisition or other transaction; and the unavailability of financing to complete
management`s plans and objectives. The forward-looking statements
contained in this press release speak only as of the date hereof and the
Company disclaims any intent or obligation to update these forward-looking
statements.
/CONTACT: Joseph W. Hovorka, President of Immune Response, Inc.,
303-796-8139; or William J. Post, President of Opticon Medical, Inc.,
614-336-2000/
06:55 EST
MFG DJ-Cool
Quelle: wallstreet-journal
Immune Response Signs Definitive Agreement to
Acquire Opticon Medical; Immune Shareholders
Approve Three Proposals At Special Shareholders
Meeting
ENGLEWOOD, Colo., Jan. 24 /PRNewswire/ -- Immune Response, Inc.
("Immune") (Nasdaq: IMUR) announced that it has signed a definitive
agreement to acquire privately held Opticon Medical, Inc. ("Opticon") through
a newly formed wholly owned subsidiary. Terms of the agreement call for the
existing stockholders of Immune to retain 20% of the newly merged company
on a post-merger basis through a tax-free exchange of stock. Upon
completion of the merger, the current officers and directors of Immune
Response will step down and a new board of directors chosen by Opticon will
take over. The current management of Opticon will operate the newly
merged company.
Opticon, based in Dublin, Ohio, is a development stage company focused on
the design, development and marketing of a series of innovative,
cost-effective devices for the management and control of adult urinary
incontinence and for use in traditional urinary management. Opticon
possesses the patents to an innovative product, the OPTICON(TM), a
disposable, silicone, indwelling valved catheter designed to prevent urine
leakage from the lower urinary tract. Unlike traditional urinary catheters, the
OPTICON does not require a system of urine collection bags and collecting
tubes.
"We are very excited to have the definitive agreement executed as we move
toward completing the transaction within the next few weeks," said William J.
Post, Opticon`s President. "This transaction will immediately enhance our
access to the public markets as we seek to make the all important step from
pure research and development to manufacturing and production."
Opticon is led by a team of officers and directors with extensive experience in
the healthcare industry. Mr. Post is a 23-year healthcare industry veteran
with significant experience in new business development and marketing. Mr.
Post has held executive level positions with healthcare companies such as
Medex, Inc., Ohmeda/BOC Healthcare and Spectramed, Inc.,
Instrumentation Laboratories, Inc. and Travenol-Genentech Diagnostics, a
division of Baxter. Opticon`s Chairman, Walter L. Sembrowich, Ph.D., is
President and founder of Aviex, Inc., a provider of investment and
development services to start-up and early stage medical companies. Dr.
Sembrowich is a founder of Diametrics Medical, Inc., a manufacturer and
marketer of a point-of-care blood analysis system, and is a director of St.
Jude Medical, a leader in cardiovascular products and technologies.
Closing of the transaction is subject to, among other things, successful
completion of final due diligence, completion of certain additional documents,
obtaining corporate and any necessary regulatory approvals, approval of the
transaction by Opticon`s shareholders, certain financing conditions, and other
customary pre-closing conditions.
Immune also announced today the results of its Special Meeting of
Shareholders held on January 20, 2000 in Denver, Colorado. At the meeting,
the Company`s shareholders approved three proposals including: a one for
three (1 for 3) reverse stock split of the Company`s common stock; a
reduction in the affirmative shareholder vote necessary to approve major
transactions from two-thirds to a majority of shares outstanding; and the
authorization to issue up to 1,000,000 shares of "blank check" preferred stock
and to increase the authorized capital of the Company to 26,000,000 shares.
The company is presently completing the paperwork necessary to effectuate
the reverse stock split and will announce the effective date in the near future.
The statements included in this press release concerning predictions of
economic performance and management`s plans and objectives constitute
forward-looking statements made pursuant to the safe harbor provisions of
Section 21E of the Securities Exchange Act of 1934, as amended, and Section
27A of the Securities Act of 1933, as amended. These statements involve
risks and uncertainties that could cause actual results to differ materially from
the forward-looking statements. Factors which could cause or contribute to
such differences include, but are not limited to, factors detailed in Immune`s
Securities and Exchange Commission filings; regulatory approvals; any
necessary stockholder approvals for either Immune or Opticon; economic
downturns affecting the operations of Immune or Opticon; the inability of
Opticon to receive necessary Regulatory approval for its products; the
inability to initiate or complete any contemplated restructuring, offering,
acquisition or other transaction; and the unavailability of financing to complete
management`s plans and objectives. The forward-looking statements
contained in this press release speak only as of the date hereof and the
Company disclaims any intent or obligation to update these forward-looking
statements.
/CONTACT: Joseph W. Hovorka, President of Immune Response, Inc.,
303-796-8139; or William J. Post, President of Opticon Medical, Inc.,
614-336-2000/
06:55 EST
MFG DJ-Cool
Na also geht doch! Sind unter den TOP 10 ohne das wir wirre Beiträge
oder wirre Boardteilnehmer dabei hätten. Es bringt zwar nichts aber
ich finde es trotzdem schön, das mehrere Investoren sich für IMNR
interessieren. Danke für die Beträge und weiter so!!!!
Grüße DJ-Cool
oder wirre Boardteilnehmer dabei hätten. Es bringt zwar nichts aber
ich finde es trotzdem schön, das mehrere Investoren sich für IMNR
interessieren. Danke für die Beträge und weiter so!!!!
Grüße DJ-Cool
Na also geht doch! Sind unter den TOP 10 ohne das wir wirre Beiträge
oder wirre Boardteilnehmer dabei hätten. Es bringt zwar nichts aber
ich finde es trotzdem schön, das mehrere Investoren sich für IMNR
interessieren. Danke für die Beträge und weiter so!!!!
Grüße DJ-Cool
oder wirre Boardteilnehmer dabei hätten. Es bringt zwar nichts aber
ich finde es trotzdem schön, das mehrere Investoren sich für IMNR
interessieren. Danke für die Beträge und weiter so!!!!
Grüße DJ-Cool
Beitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
Wertpapier | Beiträge | |
---|---|---|
243 | ||
98 | ||
97 | ||
86 | ||
78 | ||
42 | ||
37 | ||
33 | ||
33 | ||
31 |
Wertpapier | Beiträge | |
---|---|---|
29 | ||
26 | ||
26 | ||
25 | ||
24 | ||
23 | ||
22 | ||
22 | ||
21 | ||
20 |